News / Asia

Health Care Bribery in China: Why it Worries Global Drug Makers

A Chinese national flag flutters in front of a GlaxoSmithKline (GSK) office building in Shanghai, July 12, 2013.
A Chinese national flag flutters in front of a GlaxoSmithKline (GSK) office building in Shanghai, July 12, 2013.
A high-profile Chinese investigation of alleged bribery at Britain-based drug giant GlaxoSmithKline is drawing attention to the growing presence of foreign pharmaceutical companies in China's booming health care market.

The recent arrest of four Chinese GSK executives implicated in the scandal also highlights the challenges facing the foreign drug makers as they deal with deep-rooted corruption in Chinese health care and Beijing's new efforts to crack down on it.

Chinese authorities announced the arrests on Monday, saying the executives are suspected of bribing doctors, hospitals and government officials to boost sales and prices of GSK products in China.

China also has placed a travel ban on the British finance director of GSK's China division, Steve Nechelput, preventing him from leaving the country.

GSK confirmed the ban on Thursday, but said Nechelput has not been questioned or detained. It also has pledged to cooperate with Chinese authorities in combating corruption.

GSK is one of 38 multinational drug companies with research and development capabilities operating in China. An organization representing those firms, the R&D-Based Pharmaceutical Association Committee (RDPAC)), said they invested $3 billion in China from 2006 to 2010.

Growth potential

Victoria Lai, a New York-based China analyst at the Economist Intelligence Unit, told VOA that foreign drug companies see China as a crucial market to grow their business as sales slow elsewhere.

"The pharmaceutical market in China is still relatively undeveloped," she said. "The size of the market is only around 17 percent of the size of the U.S. market (by value), even though the [Chinese] population is much bigger."

The EIU says pharmaceutical sales in China reached $69 billion in 2012. It predicts those sales will more than double to $166 billion in 2017.

"By then [China] will have surpassed Japan to be the world's second biggest pharmaceutical market," Lai said. "So that is something that foreign drug makers really do not want to miss out on."

Several factors have contributed to surging purchases of pharmaceuticals in China.

"Health care coverage in the country has been expanding rapidly and incomes are rising rapidly as well," Lai said. "As China grows richer, they are experiencing more lifestyle changes leading to different diseases. For example, with changing diets, more people are getting what we would call rich world diseases, like diabetes."

Besides selling drugs in China, multinational companies also have increased research and manufacturing operations there.

Deepening investment

RDPAC says its members spent about $1 billion to build 22 R&D facilities in China from 2006 to 2010. It says 70 percent of member companies also have established Chinese manufacturing plants.

Lai said foreign companies need the R&D facilities to run clinical trials of their medications before Chinese regulators will approve them. She said Chinese officials also have been encouraging the companies to manufacture the drugs inside China.

"Part of this is because they want to boost various sectors of their economy, and biotech and pharmaceuticals manufacturing is very attractive, because it counts as higher value and can generate quite a bit of output and tax income in the future," she said.

The expansion of foreign drug makers in China also has increased their risk of involvement in corrupt practices that have plagued Chinese hospitals and clinics for decades.

Bribery risks

American firms Pfizer and Eli Lilly paid tens of millions of dollars to the U.S. government last year to settle charges of corruption in foreign markets, including China.

Wang Fangqing, a Shanghai-based health reporter for SCRIP Intelligence, told VOA it is common for drug makers, foreign and local, to pay bribes to ensure that drugs are distributed in hospitals and prescribed to patients. "GSK is definitely not alone," she said.

Many Chinese medical workers accept bribes and sell drugs at artificially high prices to supplement low incomes and weak state funding for health care. Such practices are so typical that Chinese people often refer to them by the phrase Yi Yao Yang Yi, or "feeding hospitals by selling drugs."

Wang said China launched health care reform almost a decade ago to change that system. "But little has changed," she said.

EIU analyst Lai blamed the lack of progress on poor enforcement of rules against corrupt behaviors.

"Those [drug companies] that do not adopt these practices find it really hard to compete with those that do," Lai said. "They see themselves as being left behind in terms of being prescribed to patients. This is the case not just for foreign drug makers but for local drug makers as well."

The Chinese government's investigation of GSK and other recent measures indicate that Beijing is getting tougher.

Crackdown intensifies

The State Food and Drug Administration said Wednesday it will stage a six-month operation against drug industry misconduct.

China's National Development and Reform Commission also recently launched an investigation of prices charged by 60 local and international drug makers, including units of GSK, U.S.-based Merck and Japan's Astellas Pharma.

Belgium-based company UCB said Thursday Chinese regulators have visited its offices and those of other drug makers in recent days.

Beijing is under pressure to act in response to long-running public anger about the high prices of medications not covered by state health insurance plans.

But Lai said it is too early to tell if China is serious about including domestic companies in the crackdown.

"It could be another example of Chinese investigators targeting a high profile Western company just to make a point. There is a risk that it is only targeting foreign companies to give local drug makers a bit of a leg up [boost]."

In a commentary published Thursday, Chinese state news agency Xinhua denied any attempt to "sacrifice international firms to give domestic companies unfair advantages."

Xinhua said Beijing is "firmly opposed to commercial bribery in all forms." It vowed that malpractice by "any enterprise -- Chinese, foreign or jointly-funded -- shall be punished."

Michael Lipin

Michael covers international news for VOA on the web, radio and TV, specializing in the Middle East and East Asia Pacific. Follow him on Twitter @Michael_Lipin

You May Like

Could Nemtsov Threaten Putin in Death as in Life?

Dynamic and debonair opposition leader had supported liberal economic reforms, criticized Russian president's aggression in Ukraine More

Oil Smuggling Highlights Challenges in Shutting Down IS Finances

Pentagon spokesman says Islamic State 'certainly continues to get revenue from the oil industry black market' but that airstrikes have made a dent More

India Focuses on Infrastructure, Investment to Propel Economy

Government expects economy to grow at 8 to 8.5 percent in next fiscal year More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
US Supreme Court Hears Hijab Discrimination Casei
X
Katherine Gypson
February 25, 2015 11:30 PM
The U.S. Supreme Court has heard opening arguments in a workplace religious discrimination case that examines whether a clothing store can refuse to hire a young woman for wearing the headscarf she says is a symbol of her Muslim faith. Katherine Gypson reports from the Supreme Court.
Video

Video US Supreme Court Hears Hijab Discrimination Case

The U.S. Supreme Court has heard opening arguments in a workplace religious discrimination case that examines whether a clothing store can refuse to hire a young woman for wearing the headscarf she says is a symbol of her Muslim faith. Katherine Gypson reports from the Supreme Court.
Video

Video Falling Gas Prices Hurt Nascent Illinois Hydraulic Fracturing Industry

Falling oil prices are helping consumers purchase cheaper petroleum at the pump. But that’s made hydraulic fracturing or “fracking” less economically viable for the companies in the United States invested in the process. VOA’s Kane Farabaugh reports on one Midwestern town that was hoping to change its fortunes by cashing in on the next big U.S. oil boom.
Video

Video Fighting in Sudan's South Kordofan Fuels Mass Displacement

Heavy fighting in Sudan's South Kordofan state is causing hundreds of thousands to flee into uncertain conditions. Local aid organizations estimate as many as 400,000 civilians have been internally displaced since the conflict began more than three years ago, while another 250,000 have fled across the border to refugee camps in South Sudan. VOA's Adam Bailes reports.
Video

Video Lao Dam Project Runs Into Opposition

A Lao dam project on a section of the Mekong River is drawing opposition from local fishermen, international environmental groups and neighboring countries. VOA's Say Mony visited the region to investigate the concerns. Colin Lovett narrates.
Video

Video A Filmmaker Discovers Her Biracial Identity in "Little White Lie

Lacey Schwartz grew up in an upper middle-class Jewish family, in a town in upstate New York where almost everyone she knew was white. She assumed that she was, as well. Her recent documentary, Little White Lie, tells the story of how she uncovered the secret of her true racial background. VOA’s Carolyn Weaver has more on the film.
Video

Video Deep Under Antarctic Ice Sheet, Life!

With the end of summer in the Southern hemisphere, the Antarctic research season is over. Scientists from Northern Illinois University are back in their laboratory after a 3-month expedition on the Ross Ice Shelf, the world’s largest floating ice sheet. As VOA’s Rosanne Skirble reports, they hope to find clues to explain the dynamics of the rapidly melting ice and its impact on sea level rise.
Video

Video US-Cuba Normalization Talks Resume Friday

Negotiations aimed at normalizing diplomatic relations between the U.S. and Cuba resume Friday. On the table: lifting a half-century trade embargo and easing banking and travel restrictions. There's opposition in Congress, but some analysts say there may be sufficient political and economic incentives in both nations for a potential breakthrough this year. VOA's Mil Arcega reports.
Video

Video Pakistan's Deadline For SIM Registration Has Cellphone Users Scrambling

Pakistani cell phone users have until midnight Thursday to register their SIM cards, or their service will be cut off. While some privacy experts worry about government intrusion, many Pakistanis are just worried about keeping their phone lines open. VOA Deewa reporter Arshad Muhmand has more from Peshawar.
Video

Video Myanmar Warns Factory Workers to End Strikes

Outside Myanmar's main city Yangon, thousands of workers walked off their jobs earlier this month demanding a doubling of their wages, pay raises after a year and input from labor unions on industrial regulations. Since Friday, the standoff has grown more tense as police moved in to disrupt the sit-ins, resulting in clashes that injured people from both sides. VOA correspondent Steve Herman visited industrial zones which have become a focus of Myanmar's fledgling workers rights movement.
Video

Video Oscar Winners Do More Than Thank the Academy

The Academy Awards presentation is Hollywood’s night to reward the best movies from the previous year. It’s typically a lot of glitter, a lot of thank you’s, a lot of speeches. But many of this year’s speeches carried messages beyond the thank you's. VOA’s Carolyn Presutti takes a look.

All About America

Circumventing Censorship

An Internet Primer for Healthy Web Habits

As surveillance and censoring technologies advance, so, too, do new tools for your computer or mobile device that help protect your privacy and break through Internet censorship.
More